No Data
No Data
This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Neurocrine Biosciences Publishes Positive Data From Movement Disorder Study
Neurocrine Announces Publication Of Post-Hoc Analysis From Two 48-Week Studies, KINECT 3 Extension And KINECT 4, Demonstrating Long-term Safety Profile And Robust Efficacy Of INGREZZA Capsules In Adults With TD In The Journal Of Clinical Psychiatry
Evercore ISI Group Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $185
Natera Announces That Its Ultra-Sensitive Signatera Genome Assay Is Now Broadly Available To Physicians In The United States.
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts
Hedging the Edge : Moderna, Sarepta, Biotech Stocks Sink After Top FDA Official Resigns